Methodological issues of corticosteroid use in SLE clinical trials

被引:14
作者
Corzillius, M
Bae, SC
机构
[1] Univ Kiel, Dept Internal Med 2, D-24116 Kiel, Germany
[2] Hanyang Univ, Hosp Rheumat Dis, Coll Med, Dept Internal Med,Div Rheumatol, Seoul 133791, South Korea
关键词
SLE; clinical trials; corticosteroids;
D O I
10.1191/096120399680411407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To describe and analyze how investigators handled concurrent steroid intake in SLE clinical trials; to identify remaining methodological problems and to discuss potential solutions. Methods: A review of the literature was performed in Medline to identify randomized controlled trials (RCT) in lupus published during the past decade. A set of criteria was defined a priori to analyze these trials covering different aspects of steroid use in RCTs with regard to eligibility, randomization, post-randomization steroid use, analysis and reporting. Results: Seventeen trials met the inclusion criteria and were analyzed. Median sample size was 30, ranging from 10-71. In three trials corticosteroid application was the study intervention. Three reports did not address steroid use among study subjects at all. In seven trials steroid use was part of the eligibility criteria in some way. of the trials that allowed concurrent steroid use, seven checked for equal distribution of baseline steroids. In some cases clinically relevant differences did not reach statistical significance as sample sizes were very small. In only one study was randomization stratified for steroid use. Instructions for post-randomization steroid use were specified in only 3 of 14 trials where steroids were not part of the intervention. In 11 RCTs concurrent steroid use was free or no information was provided. Steroid dosing during the intervention was reported as a secondary outcome measure in four trials. Conclusions: As sample sizes are often small, simple randomization is not reliable to avoid relevant between-group differences in baseline steroids. The power of statistical testing for group differences is limited for the same reason. Stratified randomization is rarely used. Free concurrent steroid use during the intervention is frequently allowed in lupus RCTs despite the risk of bias. Better data and accepted standards for rt priori specified steroid regimens in RCTs are highly warranted.
引用
收藏
页码:692 / 697
页数:6
相关论文
共 33 条
  • [1] ADACHI JD, 1994, J RHEUMATOL, V21, P1922
  • [2] DOES CORTICOSTEROID-THERAPY AFFECT THE SURVIVAL OF PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS
    ALBERT, DA
    HADLER, NM
    ROPES, MW
    [J]. ARTHRITIS AND RHEUMATISM, 1979, 22 (09): : 945 - 953
  • [3] ALTMAN D, 1985, LANCET, V335, P149
  • [4] Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
    Alvarez-Nemegyei, J
    Cobarrubias-Cobos, A
    Escalante-Triay, F
    Sosa-Munoz, J
    Miranda, JM
    Jara, LJ
    [J]. LUPUS, 1998, 7 (06) : 414 - 419
  • [5] Austin JS, 1996, ARTHRIT CARE RES, V9, P391, DOI 10.1002/1529-0131(199610)9:5<391::AID-ANR1790090508>3.0.CO
  • [6] 2-V
  • [7] PREVENTION OF RELAPSES IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    BOOTSMA, H
    SPRONK, P
    DERKSEN, R
    DEBOER, G
    WOLTERSDICKE, H
    HERMANS, J
    LIMBURG, P
    GMELIGMEYLING, F
    KATER, L
    KALLENBERG, C
    [J]. LANCET, 1995, 345 (8965) : 1595 - 1599
  • [8] RISK FOR SUSTAINED AMENORRHEA IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS RECEIVING INTERMITTENT PULSE CYCLOPHOSPHAMIDE THERAPY
    BOUMPAS, DT
    AUSTIN, HA
    VAUGHAN, EM
    YARBORO, CH
    KLIPPEL, JH
    BALOW, JE
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (05) : 366 - 369
  • [9] CHEE YC, 1993, SINGAPORE MED J, V31, P15
  • [10] Clark W F, 1991, J Clin Apher, V6, P40, DOI 10.1002/jca.2920060109